Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marina, N.
Right arrow Articles by Gorlick, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marina, N.
Right arrow Articles by Gorlick, R.
The Oncologist, Vol. 9, No. 4, 422–441, July 2004
© 2004 AlphaMed Press

Biology and Therapeutic Advances for Pediatric Osteosarcoma

Neyssa Marinaa, Mark Gebhardtb, Lisa Teotc, Richard Gorlickd

a Department of Pediatrics, Division of Hematology-Oncology, Stanford University Medical Center, Stanford, California, USA; b Department of Orthopedic Surgery, Children’s Hospital, Boston, Massachusetts, USA; c Department of Pathology, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA; d Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Correspondence: Neyssa Marina, M.D., Stanford University Medical Center, 300 Pasteur Drive, Room G313, Stanford, California 94305-5208, USA. Telephone: 650-723-5535; Fax: 650-723-5231; e-mail: Neyssa.marina{at}stanford.edu

Osteosarcoma is the most common malignant bone tumor in children and adolescents. Survival for these patients was poor with the use of surgery and/or radiotherapy. The introduction of multi-agent chemotherapy dramatically improved the outcome for these patients and the majority of modern series report 3-year disease-free survival of 60%–70%. This paper describes current strategies for treating patients with osteosarcoma as well as review of the clinical features, radiologic and diagnostic work-up, and pathology. The authors review the state of the art management for patients with osteosarcoma in North America and Europe including the use of limb-salvage procedures and reconstruction as well as discuss the etiologic and biologic factors associated with tumor development. Therapy-related sequelae and future directions in the biology and therapy for these patients are also discussed.

Key Words. Pediatric osteosarcoma • Therapy • Biology • Multidisciplinary treatment • Therapeutic advances




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. C. Manara, G. Nicoletti, D. Zambelli, S. Ventura, C. Guerzoni, L. Landuzzi, P.-L. Lollini, S.-M. Maira, C. Garcia-Echeverria, M. Mercuri, et al.
NVP-BEZ235 as a New Therapeutic Option for Sarcomas
Clin. Cancer Res., January 15, 2010; 16(2): 530 - 540.
[Abstract] [Full Text] [PDF]

Home page
 In VivoHome page
K. E. COMSTOCK, C. L. HALL, S. DAIGNAULT, S. A. MANDLEBAUM, C. YU, and E. T. KELLER
A Bioluminescent Orthotopic Mouse Model of Human Osteosarcoma that Allows Sensitive and Rapid Evaluation of New Therapeutic Agents In Vivo
In Vivo, September 1, 2009; 23(5): 661 - 668.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
T. A. Guise, R. O'Keefe, R. L. Randall, and R. M. Terek
Molecular Biology and Therapeutics in Musculoskeletal Oncology
J. Bone Joint Surg. Am., March 1, 2009; 91(3): 724 - 732.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Akiyama, C. R. Dass, and P. F.M. Choong
Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway
Mol. Cancer Ther., November 1, 2008; 7(11): 3461 - 3469.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Ketola, A. Hinkkanen, F. Yongabi, P. Furu, A.-M. Maatta, T. Liimatainen, R. Pirinen, M. Bjorn, T. Hakkarainen, K. Makinen, et al.
Oncolytic Semliki Forest Virus Vector as a Novel Candidate against Unresectable Osteosarcoma
Cancer Res., October 15, 2008; 68(20): 8342 - 8350.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
I. Scionti, F. Michelacci, M. Pasello, C. M. Hattinger, M. Alberghini, M. C. Manara, G. Bacci, S. Ferrari, K. Scotlandi, P. Picci, et al.
Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma
Ann. Onc., August 1, 2008; 19(8): 1500 - 1508.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
A. Spreafico, S. Schenone, T. Serchi, M. Orlandini, A. Angelucci, D. Magrini, G. Bernardini, G. Collodel, A. Di Stefano, C. Tintori, et al.
Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells
FASEB J, May 1, 2008; 22(5): 1560 - 1571.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
N. V. Koshkina, C. Khanna, A. Mendoza, H. Guan, L. DeLauter, and E. S. Kleinerman
Fas-Negative Osteosarcoma Tumor Cells Are Selected during Metastasis to the Lungs: The Role of the Fas Pathway in the Metastatic Process of Osteosarcoma
Mol. Cancer Res., October 1, 2007; 5(10): 991 - 999.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
X. Wan and L. J. Helman
The Biology Behind mTOR Inhibition in Sarcoma
Oncologist, August 1, 2007; 12(8): 1007 - 1018.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Hicks, J. R. Roth, C. A. Kozinetz, and L. L. Wang
Clinicopathologic Features of Osteosarcoma in Patients With Rothmund-Thomson Syndrome
J. Clin. Oncol., February 1, 2007; 25(4): 370 - 375.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pediatric Oncology NursingHome page
E. Hendershot, A. Pappo, D. Malkin, and L. Sung
Tumor Necrosis in Pediatric Osteosarcoma: Impact of Modern Therapies
Journal of Pediatric Oncology Nursing, July 1, 2006; 23(4): 176 - 181.
[Abstract] [PDF]

Home page
 JCOHome page
L. Kager, A. Zoubek, U. Kastner, B. Kempf-Bielack, J. Potratz, R. Kotz, G. U. Exner, C. Franzius, S. Lang, R. Maas, et al.
Skip Metastases in Osteosarcoma: Experience of the Cooperative Osteosarcoma Study Group
J. Clin. Oncol., April 1, 2006; 24(10): 1535 - 1541.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. S. Petrilli, B. de Camargo, V. O. Filho, P. Bruniera, A. L. Brunetto, R. Jesus-Garcia, O. P. Camargo, W. Pena, P. Pericles, A. Davi, et al.
Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: Prognostic Factors and Impact on Survival
J. Clin. Oncol., March 1, 2006; 24(7): 1161 - 1168.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
K. L. Weber
What's New in Musculoskeletal Oncology
J. Bone Joint Surg. Am., June 1, 2005; 87(6): 1400 - 1410.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2004 by AlphaMed Press.
Advertisement